Hepatitis C (cont.)
In this Article
- Hepatitis C infection (HCV, hep C) facts
- What is hepatitis C infection?
- What are the symptoms of hepatitis C infection?
- How is hepatitis C spread, and is it contagious?
- What conditions beyond the liver are associated with hepatitis C infection?
- Who is at high risk and should be tested for hepatitis C infection?
- What is the usual progression of chronic hepatitis C infection?
- How is hepatitis C diagnosed?
- What is the treatment for hepatitis C infection?
- Newer drugs and therapeutic medications for hepatitis C
- Who should receive antiviral therapy for hepatitis C virus infection?
- Who should not receive treatment with antiviral therapy?
- How effective is hepatitis C treatment?
- What are the goals of therapy for hepatitis C infection?
- What are the side effects of treatment for hepatitis C infection?
- Hepatitis C and liver transplantation
- How is monitoring done before, during and after treatment?
- Can hepatitis C be prevented?
- What is the current research and what is in the future for hepatitis C?
- Hepatitis C FAQs
- Find a local Gastroenterologist in your town
How effective is hepatitis C treatment?
Treatment responses are mainly defined by results of the HCV RNA testing. The patterns of response to antiviral treatment have been described as follows:
- rapid viral response
- end of treatment response
- sustained virologic response,
- partial response
- no response
Rapid viral response: Rapid viral response is defined as the absence of detectable HCV RNA in serum using a sensitive test 4 weeks after initialing treatment. Favorable response this early predicts longer term treatment success.
End of treatment response: End of treatment response is defined as absence of HCV RNA in blood using a sensitive test at the end of treatment, whatever duration of treatment has been chosen.
Sustained virologic response: The optimal response is a sustained virologic response (SVR), defined as the absence of detectable HCV RNA in serum using a sensitive test at the end of the treatment and six months later. Most of these individuals will remain in remission (no signs of the disease) indefinitely, with no detectable hepatitis C virus RNA in the blood or liver. Moreover, follow-up biopsies show a marked reduction in inflammation and there even can be regression of scarring. Longer follow-up of these patients is necessary, however, to evaluate definitively whether sustained responders will avoid the complications of cirrhosis and live longer.
Relapsers: Relapsers are patients who initially eliminate the RNA from their blood, but then develop detectable RNA again shortly after discontinuing therapy. The RNA becomes detectable again within six months and usually within the first three months of stopping treatment.
Partial responders: Patients whose HCV RNA levels decline (two log decrease), but never become undetectable at 24 weeks are referred to as partial responders.
No response: Patients who have sustained levels of detectable HCV RNA during therapy are known as non-responders. Patients in whom HCV RNA becomes undetectable during the early period of treatment, but reappears before the end of therapy should probably likewise be considered non-responders. This reappearance of HCV RNA during therapy is referred to as a 'break through' of HCV.
Find out what women really need.